Logo-uniQure-MS-Word_Orange.jpg
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
17. November 2022 07:05 ET | uniQure Inc.
~ Event to be Webcast Live on uniQure’s Corporate Website at 8:30 a.m. EST ~ LEXINGTON, Ma. and AMSTERDAM, Nov. 17, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy...
Cyclacel Pharmaceuticals logo
Cyclacel Hosting Research & Development Day
24. Oktober 2022 09:15 ET | Cyclacel
-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma- -Monday, October 31st @ 10 am ET- ...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022
13. April 2022 08:00 ET | Praxis Precision Medicines, Inc.
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics to Host R&D Day on October 21, 2021
07. Oktober 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics to Host R&D Day on October 21, 2021 7 October 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery,...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020
01. Dezember 2020 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that the Company will host a virtual R&D Day on Wednesday, December 9, 2020 at 12:00 p.m. ET to...
Surface Logo New Version-color.png
Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day
18. November 2019 06:30 ET | Surface Oncology, Inc.
Details clinical plans for phase 1/1b clinical studies of SRF617 and SRF388 in patients with advanced solid tumors Shares preclinical data for new, CD112R targeted antibody candidate, SRF813, and its...
Summit Master_rgb_png.png
Summit Therapeutics to Host R&D Day 7 October 2019
25. September 2019 07:00 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Host R&D Day 7 October 2019 Oxford, UK, and Cambridge, MA, US, 25 September 2019 – Summit Therapeutics plc...
Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day
26. März 2019 06:00 ET | Autolus Therapeutics plc
LONDON, March 26, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the...
logo_new.jpg
ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations
07. Dezember 2018 12:12 ET | ObsEva SA
       Clinical Trial Data and Regulatory Progress on Lead Programs Targeting IVF, Endometriosis, and Uterine Fibroids to Transform Company in 2019 GENEVA, Switzerland and BOSTON, Mass. (December...
logo_new.jpg
ObsEva SA to Host R&D Investor Day December 7, 2018
29. November 2018 01:30 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – November 29, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics...